Bladder — In Follow-up

Non-muscle invasive bladder cancer is common and can cause substantial suffering. If the cancer is “high risk” then in over 30% of people it can turn into a more aggressive form of bladder cancer that requires treatment such as removal of or radiotherapy to the bladder within 5 years despite best current treatment. This risk can be reduced by placing BCG bacteria into the bladder. Recent preliminary studies show promising results from also placing mitomycin, a chemotherapy drug, into the bladder along with BCG treatment. This large-scale, randomised trial will determine the effects of adding mitomycin to BCG on cure rates, survival, side effects, and quality of life.
If you think this trial might be right for you, please ask your doctor.
Trial Title
Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a randomised phase III trial
Cancer Type
Trial Status
In Follow-up
Protocol Number
ANZUP 1301
Co-ordinating centre
Study Chair
Professor Dickon Hayne
Patient Population
Adults with resected, high-risk NMIBC (high grade Ta or any grade T1) suitable for intravesical chemotherapy treatment.
Recruitment Target
Stage 1: 130 patients Stage 2: 370 patients
Detailed Information
Further Information
Latest Publication
Participating Centres
Concord Repatriation General Hospital
Westmead Hospital - Western Sydney Local Health District
John Hunter Hospital
Northern Cancer Institute
Southside Cancer Care Centre
The Tweed Hospital
Nepean Hospital
Sydney Adventist Hospital

Epworth HealthCare (Richmond)
Royal Melbourne Hospital
Alfred Health - The Alfred Hospital
Austin Health
Frankston Hospital
Western Health - Footscray Hospital

Redcliffe Hospital

Fiona Stanley Hospital

Nottingham University Hospitals NHS Trust - City Hospital Campus